Tremfya™ (guselkumab) is a biologic approved for the treatment moderate-to-severe plaque psoriasis in...
- Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
- Genentech doses first patient in Perjeta and Herceptin Phase 3 study
- Combining antibiotics with immune response to treat antibiotic resistant bacteria
- May’s top news stories
- Algorithm optimises peptides to target drug-resistant bacteria
Mitochondrial Testing Services
Mitochondria are present in every cell of the body. They maintain cell homeostasis by controlling energy production, ion fluxes and the rate-limiting step of steroidogenesis.
April’s top news stories
Chinese clinical-stage biopharmaceutical company I-Mab Biopharma and German biotech company MorphoSys have begun the first dosed Phase III clinical study to assess investigational human CD38 antibody TJ202/MOR202 in combination with lenalidomide in patients suffering from relapsed or refractory multiple myeloma; and A small clinical trial by researchers at the University of Edinburgh in the UK has showed that cilostazol and isosorbide mononitrate could prevent recurrence of stroke and vascular dementia. Drugdevelopment-technology.com wraps up the key headlines from April 2019.
Detecting the Presence of Trace Polymorphs and Impurities
In the pharmaceutical industry, the detection of polymorph traces is one of the most important applications of powder x-ray diffraction (PXRD).
Eligen® Technology Mechanism of Action
Emisphere's Eligen® Technology binds a delivery agent with a therapeutic compound without alternation. This process occurs when both agent and compound are in close proximity.
February’s top news stories
Eidos Therapeutics commenced a pivotal Phase III clinical trial of its investigational small molecule AG10 for the treatment of transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM), and Immatics is set to study its investigational therapy IMA101 in combination with Roche’s Tecentriq (atezolizumab) drug for the treatment of solid cancers. Drugdevelopment-technology.com wraps up key headlines from February 2019.
Cabometyx (cabozantinib) for Treatment of Patients with Advanced Renal Cell Carcinoma
Cabometyx (cabozantinib) is used for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC).
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.